Effect and mechanism of protease inhibitor oprozomib on doxorubicin sensitivity of hepatocellular carcinoma cells

• Hoofdauteurs: Feng Qi (Auteur), Sheng Zheng (Auteur), Lu Hou (Auteur), XinNian Fu (Auteur), XinXin Wang (Auteur), ZhiPeng Fu (Auteur), Juan Yang (Auteur)
• Formaat: Boek
• Gepubliceerd in: Polskie Towarzystwo Farmaceutyczne, 2024-06-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

This study was to examine the impact of Oprozomib (OPZ), an oral second-generation proteasome inhibitor, on the sensitivity of hepatocellular carcinoma (HCC) cells to doxorubicin (DOX), a commonly used chemotherapy drug for the treatment of HCC. HCC cells were incubated with OPZ or DOX. Cell prolife...